Back to top

UBS Sticks to Its Buy Rating for CSL (CMXHF)

In a report released today, David Low from UBS maintained a Buy rating on CSL, with a price target of A$158.00. Low covers the Healthcare sector, f...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Carlisle Companies Incorporated (CSL)

CSL Limited Sponsored ADR (CSLLY)